Express Pharma

NIPER to organise national conference on bulk drugs

244

Discussions will be held on opportunities for growth, challenges and way forward

National Institute of Pharmaceutical Education and Research (NIPER), (Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India), will organise a national conference on ‘Innovative processes for bulk drugs, enabling the processes of tomorrow,’ in Hyderabad on March 26 and 27, 2015.

The conference is aimed at discussing the opportunities for growth, challenges and way forward. Reputed industry experts, academicians and policy makers are expected to take part in the conference. The conference will also host vibrant and interactive poster sessions. A subset of the posters will be selected for oral presentations.

The conference will have sessions focused on the following themes. They are greener catalysts for pharma processes; development of new pharma strategies & technologies; use of continuous micro reactor technologies; biocatalysts & bioprocesses; process development & scale-up for pharmaceutical products; opportunities and challenges in biopharmaceutical development; advances in quality methods (QBD); impurity profiling; regulatory challenges; process safety in the scale-up; IP landscape in API and generic industries.

Speakers who will take part in the conference are Dr AKS Bhujanga Rao, Natco Pharma, Hyderabad; Dr Vaidyanathan Rajappa, Biocon BMS Research Centre, Banglore; Dr Premnath Shenoy, Astra Zeneca, Bangalore; Dr Vilas Dahunkar, Dr Reddy’s Laboratories, Hyderabad; Dr Kaptan Singh, Ranbaxy laboratories, Gurgaon; Dr Amol A Kulkarni, NCL, Pune; Dr Raghu V Palle, Biocon, Banglore; Dr MV Suryanarayana, Mylan Laboratories, Hyderabad; Dr Satish Nigam, Albany Molecular Research, Hyderabad; Dr A Veera Reddy, Suven Life Sciences, Hyderabad; Dr Rakeshwar Bandichor, Dr Reddy’s Laboratories, Hyderabad; Dr S Padmaja, IproPat, Hyderabad; Dr Srinivas Oruganti, Dr Reddy’s Institute of Life Sciences, Hyderabad.

EP News bureauMumbai

- Advertisement -

Comments are closed.